Cortexyme (NASDAQ: CRTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.550 | -0.720 | -0.1700 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cortexyme (NASDAQ: CRTX) through any online brokerage.
Other companies in Cortexyme’s space includes: Alzamend Neuro (NASDAQ:ALZN), Fortress Biotech (NASDAQ:FBIO), HOOKIPA Pharma (NASDAQ:HOOK), Orchard Therapeutics (NASDAQ:ORTX) and Galectin Therapeutics (NASDAQ:GALT).
The latest price target for Cortexyme (NASDAQ: CRTX) was reported by Credit Suisse on Wednesday, May 11, 2022. The analyst firm set a price target for 3.50 expecting CRTX to rise to within 12 months (a possible 38.89% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Cortexyme (NASDAQ: CRTX) is $2.52 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cortexyme.
Cortexyme’s Q2 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for Cortexyme.
Cortexyme is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.